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Abstract
The General Data Protection Regulation (GDPR) came into force in May 2018. The aspiration of providing for a high level
of protection to individuals’ personal data risked placing considerable constraints on scientiﬁc research, which was contrary
to various research traditions across the EU. Therefore, along with the set of carefully outlined data subjects’ rights, the
GDPR provides for a two-level framework to enable derogations from these rights when scientiﬁc research is concerned.
First, by directly invoking provisions of the GDPR on a condition that safeguards that must include ‘technical and
organisational measures’ are in place and second, through the Member State law. Although these derogations are allowed in
the name of scientiﬁc research, they can simultaneously be challenging in light of the ethical requirements and well-
established standards in biobanking that have been set forth in various research-related soft legal tools, international treaties
and other legal instruments. In this article, we review such soft legal tools, international treaties and other legal instruments
that regulate the use of health research data. We report on the results of this review, and analyse the rights contained within
the GDPR and Article 89 of the GDPR vis-à-vis these instruments. These instruments were also reviewed to provide
guidance on possible safeguards that should be followed when implementing any derogations. To conclude, we will offer
some commentary on limits of the derogations under the GDPR and appropriate safeguards to ensure compliance with
standard ethical requirements.
Introduction
The General Data Protection Regulation (GDPR) seeks to
ensure the free movement of data throughout the European
Union (EU) and give expression to the right to personal data
protection within and beyond the EU, as long as an EU data
subject’s data or data collected in the EU are being pro-
cessed. It details, the lawful basis of the processing of
data (Article 6) and delineates prohibitions for processing
special categories of data, such as health and genetic data
(Article 9), sets out the conditions for consent (Article 7),
outlines the individual rights of data subjects (Articles
13–22), and provides data subjects with a mechanism to
enforce their rights (Articles 77–84).
The EU aspiration to provide a high level of protection to
individuals’ personal data risked placing considerable con-
straints on scientiﬁc research, which was contrary to various
research traditions across the EU. Therefore, along with the
set of carefully outlined data subjects’ rights, the GDPR
also provides for a two-level framework to enable deroga-
tions from these rights when scientiﬁc research is con-
cerned. First, by directly invoking provisions of the GDPR
on a condition that derogations be subject to safeguards that
must include ‘technical and organisational measures’, and
second, through the Member State law and subject to
safeguards.
Although these derogations are allowed in the name of
scientiﬁc research, they can simultaneously be seen as
challenging in light of the ethical requirements and long-
standing protection standards for participants in biobanking
that have been established in various research-related soft
legal tools, international treaties and other legal instruments.
In relation to the use of broad consent, the GDPR itself
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explicitly references such standards and Recital 33 states
that it is permitted to give ‘consent to certain areas of sci-
entiﬁc research when in keeping with recognised ethical
standards for scientiﬁc research’. The recognition of ethical
standards is here related to broad consent and there is no
explicit requirement to consider derogations in line with
these ‘recognised ethical standards for scientiﬁc research’.
Hence, research that could be deemed legal under the
GDPR or Member State laws that permits further deroga-
tions, might not necessarily be in line with ethical standards
that are currently required by research ethics committees
(RECs). In other words, a gap between the ethical standard
and legal requirements could emerge.
In this article, we review such soft legal tools, interna-
tional treaties and other legal instruments (collectively
referred to here as ‘instruments’) that regulate the use of
health research data. We report on the results of this review,
and analyse the rights contained within the GDPR and
Article 89 of the GDPR vis-à-vis these instruments. These
instruments were also reviewed to provide guidance on
possible safeguards that should be followed when imple-
menting any derogations. To conclude, we will offer some
commentary on limits of the derogations under the GDPR
and appropriate safeguards to ensure compliance with
standard ethical requirements.
The ethical concerns related to biobanking
Ethical consideration for biobank-based biomedical
research strike a balance between the societal need for
scientiﬁc development and individual’s dignity and auton-
omy. The Taipei declaration states that ‘[r]esearch should
pursue science advancement and public health development
while respecting the dignity, autonomy, privacy and con-
ﬁdentiality of individuals’. Those rights do not include only
the direct risks for individuals of being re-identiﬁed as ‘the
rights to autonomy, privacy and conﬁdentiality also entitle
individuals to exercise control over the use of their personal
data and biological material’.
In fact concerns about research aims may be unrelated to
‘re-identiﬁability’ but rather related to possible uses in
research, potentially against one person’s ethical beliefs
(use of health and genetic data to proﬁle families and new
generations, gender proﬁling, race proﬁling, communities
discrimination, biological weapons based on genetic spe-
ciﬁcities etc.). Concerns about possible actors involved in
the use of data (insurances, private companies etc.) are also
major issues as an individual’s willingness to participate in
research is often based on trust in speciﬁc institutions.
Biobank research is based on long-term organised col-
lections of data and samples that can potentially be used for
very diverse research aims. At the time of the collection it is
unlikely that the researcher can carefully and truly inform
participants on all possible future research uses, but it is
possible to provide good information on the governance of
data. Recent instruments show that consent (previously the
main legal basis in which to lawfully conduct research) has
been in fact paired with strong governance measures and
third party oversight mechanisms to be adopted by institu-
tions to regulate sharing, accessing and use of the data.
Making public governance procedures on decision making
is part of the trustworthiness of an institution and has
‘replaced’ in some cases speciﬁc consent as a hardly
implementable option [1, 2]. Strong governance and ethical
oversight has been proposed to support the oversight of
waivers of consent in the biobank practice [3] along with
forms of ongoing dynamic options [4]. Detailed governance
information comprising oversight policies are usually
available to participants at the time of consent.
Processing of data including secondary uses is a very
sensitive area in research, not only from a legal point of
view but also from an ethical one. Those concerns lead to a
great emphasis on principles of transparency, trust and
partnership and to the development of models for ongoing
information and dynamic consent accounting for changing
landscapes of uses including secondary ﬁndings [5].
The GDPR provisions on research are built on excep-
tions and national derogations to a law that otherwise is
committed to paying great attention to human rights.
However, it is unclear whether those provisions are
balanced by appropriate safeguards or if they are challen-
ging recent advancement in ethics, leading one to question
whether a project that is legally compliant under the GDPR
is in fact ethically compliant.
The ethical rip-off: GDPR perspectives on
data subject and biobanking
Lawful processing of data under the GDPR
Article 6 GDPR sets forth legality requirements, but these
requirements must be viewed jointly with the special pro-
tection afforded to special categories of data, including
health and genetic data under Article 9 GDPR. Generally
for biobanking purposes, the following three lawfulness
basis are of particular relevance. First, the data subject’s
consent under Article 6 (1)(a). Second, the performance of a
task carried out in the public interest under Article 6(1)(e).
Third, processing is necessary for the purposes of the
legitimate interests pursued by the controller or by a third
party under Article 6(1)(f), except where such interests are
overridden by the interests or fundamental rights and free-
doms of the data subject, which require protection of per-
sonal data, in particular where the data subject is a child.
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A distinction can be drawn between primary research and
secondary biomedical research based on data and samples.
While lawful basis of primary research could be consent
based, which might not necessarily be so for secondary use
of personal data or research using residual biological
material. In the latter cases, the claim of legitimate interest
is of particular importance. When data are not processed
based on the individual’s consent, the requirements set in
Article 6(4) shall be met, which includes the existence of
appropriate safeguards.
Article 9(1) prohibits the processing of special informa-
tion that includes genetic information, but Article 9(2)(j)
allows for processing the genetic data as part of a special
category of data if ‘processing is necessary for archiving
purposes in the public interest, scientiﬁc or historical
research purposes or statistical purposes.’ Furthermore,
additional measures could be taken under Article 9(4)
GDPR, through which Article 9(2) GDPR scope may be
implicitly expanded allowing further conditions for
processing health and genetic data, or constraining it. When
applying Article 9(2)(j), this processing must be ‘in accor-
dance with Article 89(1) based on Union or Member State
law, which shall be proportionate to the aim pursued,
respect the essence of the right to data protection and pro-
vide for suitable and speciﬁc measures to safeguard the
fundamental rights and the interests of the data subject.’ In
other words, for example, a Member State may attribute
particular value to biobank research; they may limit a data
subjects right to control the use of their data in research by
removing the consent requirement for the processing of
genetic data in biobanking, provided the national law
respects the principle of proportionality, the essence of the
right of data protection, and provides for suitable and spe-
ciﬁc measures to safeguard the rights and interests of data
subjects. Yet, as further below is discussed, the GDPR is
not very informative on these measures.
Individual rights and research-related derogations
under GDPR
The GDPR provides data subjects with a number of rights.
In biobanking, the following are of key importance: right to
information (in particular, Art. 12–14), access rights
(Art. 15), right to rectiﬁcation (Art. 16), right to erasure
(Art. 17), right to restriction of processing (Art. 18), right to
data portability (Art. 20), right to object (Art. 21). Addi-
tional protective measures include, for example, a notiﬁca-
tion entitlement, providing the data subject has triggered it
(Art. 19). Further to these rights and protection measures, at
the data subject’s disposal is access to justice, including
remedies, liability and penalties (Art. 77–84). However, this
set of rights does not seem to be at the data subject’s dis-
posal in all cases in biobank research. The exact set of rights
at the data subject’s disposal depends on several circum-
stances, key being whether the Member State has derogated
from the GDPR provisions under Article 89.2 GDPR, and/
or the biobank relies on derogations through directly
invoking the GDPR provisions under Article 89(1) GDPR
and subsequent provisions throughout the GDPR.
Article 89(1) GDPR enables processing of genetic data
for scientiﬁc research purposes, if there are appropriate
safeguards for the rights and freedoms of the data subject.
While the GDPR does not exhaustively specify what those
safeguards are, it indicates their purpose is to ‘ensure that
technical and organisational measures are in place in par-
ticular in order to ensure respect for the principle of data
minimisation.’ These measures may include pseudonymi-
sation provided it enables meeting the intended research
purposes. In situations where data are not collected directly
from the subject (e.g., residual material use), data subject’s
right to information under Article 14 could be derogated
from. Other rights that can be derogated from include the
right to erasure under Article 17, as well as the right to
object under Article 21.
In addition to these rights, EU or Member State law may
provide for derogations from a set of other rights, provided
that appropriate safeguards for the rights and freedoms of
the data subject are in place. These derogations relate to the
data subject’s access rights (Art. 15), right to rectiﬁcation
(Art. 16), right to restriction of processing (Art. 18), as well
as right to object (Art. 21), and as speciﬁed in Article 89(2)
GDPR, they can be applied if the derogations are necessary
for research purposes.
While the data subject could remain with the data port-
ability rights and additional protective measures, namely,
the notiﬁcation entitlement, these measures have a rather
limited scope. First, the notiﬁcation entitlement is closely
related to information. If the data subject’s right to infor-
mation is waived, the notiﬁcation entitlement under Article
19 could be affected. Data portability, however, has a rather
limited scope and it is inapplicable if biobank research
relates to the performance of a task carried out in the public
interest, as stated in Article 20 [6].
The potential scope of the research exemptions by
directly invoking the GDPR and through the Member State
laws that enables further derogations is so wide that, if
applied to its full extent, not only is a data subject’s consent
not necessary for the processing of personal data for
research, but also the data subject can be stripped from a
number of rights and others can be rendered ineffective,
leaving the data subject with an enforcement mechanism
only. This means, if, for example, data subjects do become
aware of processing their data for biobank research, they
might have no right to access information on this research
or object to the research. The data subject could have no
right to restrict the use of their data for research, correct any
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errors or request to erase the data. They would, however, be
able to lodge a complaint with the data protection authority,
and thus could retain some oversight [7]. However, one can
then question the effectiveness of such a mechanism from a
data subject’s perspective if there are no rights on the part of
data subject what to oversee. The research exemption could
thus undo many of the stated aims of the GDPR for
research, and put at stake its own objective—the protection
of privacy.
Methods
Soft legal tools, international treaties and other legal
instruments (hereinafter collectively called ‘instruments’)
that are inﬂuential on the regulation of health research were
identiﬁed. Our review was limited to instruments that may
be relevant to some or all Member States of the EU, which
are either directly applicable to the Member States or to
certain professions within the Member States. Our review
did not include international consortia guidelines. A code-
book was developed by CS and DM. All instruments were
imported into Nvivo 11 and coded using thematic content
analysis. A summary of the reviewed legally binding
instruments can be found in Table 1, instruments binding on
particular bodies can be found in Table 2 and legally per-
suasive instruments can be found in Table 3.
Results
While the GDPR grants a number of rights to the data
subjects (and simultaneously takes them away for research
purposes), the focus of the other instruments is on the
safeguards that must be in place for research participant
data. Two exceptions are the right to information and the
right to access.
Right to information
The requirements around information in the reviewed
instruments is generally bound up with the consent
requirements. All instruments, with the exception of the
2007 OECD Guidelines, have requirements regarding con-
sent. It is clear from the instruments reviewed that the
preference is in favour of speciﬁc, informed and written
consent, where possible. Information is requested in all
guidelines and should be given in plain language.
All legally binding instruments refer to the importance of
informed consent, but do not necessarily set it as an obli-
gatory pre-condition for secondary research. In addition, the
GDPR introduces the possibility for electronic online con-
sent as a viable option, provided the consent is clear and
concise (Recital 32). Under the GDPR, a data subject must
be informed about (among others) the identity and contact
details of the data controller, the data protection ofﬁcer,
Table 1 Instruments reviewed
Instrument Year Publishing body Applicable to
1. GDPR 2016 European Union Any company/entity, which processes personal data as
part of the activities of one of its branches established in
the EU, regardless of where the data are processed; or a
company established outside the EU offering goods/




and Freedoms of the
European Union
2000 European Union Member States of the EU in so far as they are
implementing/applying EU law
3. Council of Europe 1953 European Convention on Human Rights Member States of the Council of Europe and Members
States of the EU
4. Council of Europe 1997 Convention for the Protection of Human Rights and
Dignity of the Human Being with regard to the
Application of Biology and Medicine: Convention on
Human Rights and Biomedicine (Oviedo Convention)
Twenty-nine states that have signed and ratiﬁed the
Convention (a further ﬁve have signed but not ratiﬁed)
5. Council of Europe 1980 (revised 2018) Convention for the protection of individuals with regard
to the processing of personal data
States that have signed and ratiﬁed the Convention
6. United Nations 1966 International Convention on Economic, Social and
Cultural Rights
Countries that have ratiﬁed the Convention
Table 2 Instruments binding on particular bodies
Instrument Year Publishing body Applicable to
1. Declaration of Helsinki The 2013 edition World Medical Association Doctors (but persuasive for all
health researchers)
2. Declaration of Taipei on Ethical Considerations
Regarding Health Databases and Biobanks
2002 (revised 2016) World Medical Association Doctors (but persuasive for all
health researchers)
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the purposes for which the data will be processed, the
recipients of the data, the duration of storage and the right
to withdraw consent if consent is the lawful basis of
processing (Article 13). The 2016 Council of Europe
Recommendation requires that participants be informed of
the conditions applicable to the storage of the materials,
including access and possible transfer policies and any
relevant conditions governing the use of the materials,
including re-contact and feedback (Article 10). The Council
of Europe 2018 Convention mandates data subjects to be
told the legal basis and the purposes of the intended
processing, the categories of personal data processed, the
recipients or categories of recipients of the personal data,
and their rights as a data subject (Article 8).
Eminent guidance comes from the World Medical
Association (WMA), historically among the ﬁrst institutions
to convey ethical rules for research. Its instruments sets
professional standards for doctors, and are of importance in
the regulation of health research globally. The Declaration
of Helsinki requires that participants be informed of the
aims of the research, methods, sources of funding, any
possible conﬂict of interests, beneﬁts and risks, institutional
afﬁliations of the researchers and any other relevant infor-
mation (Principle 26). The WMA Taipei Declaration seeks
to regulate health databases and biobanks and provides
more details on the requirements for consent: participants
have to be informed about the purpose, the risks and bur-
dens, storage and use of data and material, the nature of the
data or material to be collected, the procedures for return of
results including incidental ﬁndings, the rules of access to
the health database or biobank, the protection of privacy,
the governance arrangements, procedures to inform parti-
cipants about the impact of anonymisation of data, their
fundamental rights and safeguards as established in the
Declaration, and when applicable, commercial use and
beneﬁt sharing, intellectual property issues and the transfer
of data or material to other institutions or third countries
(Article 12).
Allied with this extensive right to information, are the
provisions on the right to withdraw consent and the obli-
gation to inform data subjects about this right. Article 7(3)
of the GDPR states that data subjects can withdraw their
consent at any time and that it ‘shall be as easy to withdraw
as to give consent’. The UNESCO Declaration on Bioethics
(Article 6(1)), the Taipei Declaration (Article 15) and the
2017 OECD Recommendation (Article 5(2)) states that
there must be procedures in place to accommodate with-
drawal of consent. CIOMS states that participants need to
be informed of their right to withdraw their consent, pro-
cedures need to be put in place, any withdrawal should be
formalised and written, and future use of data are not per-
mitted after this withdrawal.
Most instruments do recognise the limits on the with-
drawal of consent. The 2009 OECD Guideline states that at
the time of consent participants must be informed about the
limits of a withdrawal of consent (Principle 4.G) as does the
2016 Council of Europe Recommendation (Article 13).
Speciﬁcally, this can only be done for identiﬁed genetic data
(UNESCO Declaration on Genetic Data, 2016 CoE
Recommendation). It is not clear whether these limitations
go beyond the practical limitation of the non-removal of
anonymous data. Withdrawal of consent is thus seen of
importance in both legally binding and other instruments
where the legal processing of data are based on consent, but
the limits on this withdrawal is recognised. Instruments that
are of persuasive value state that the limits on the with-
drawal of consent should be communicated to the
participants.
Table 3 Legally persuasive instruments
Instrument Year Publishing body Applicable to
1. Recommendation CM/Rec(2016)6 of the Committee of Ministers
to member States on research on biological materials of human
origin
2016 Council of Europe 47 Member States of the
Council of Europe
2. Recommendation on Health Data Governance 2017 OECD 35 Member States
3. OECD Guidelines on Human Biobanks and Genetic Research
Databases
2009 OECD 35 Member States
4. Principles and Guidelines for Access to Research Data from Public
Funding
2007 OECD 35 Member States
5. Universal Declaration on Human Rights 1948 UN
6. Universal Declaration on Bioethics and Human Rights 2005 UNESCO UN Members
7. International Declaration on Human Genetic Data 2003 UNESCO UN Members
8. Universal Declaration on the Human Genome and Human Rights 1997 UNESCO UN Members
9. International Ethical Guidelines for Health-related Research
Involving Humans
2016 Council for International
Organizations of Medical Sciences
Health-related researchers
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Right to access
The GDPR, the Council of Europe 2018 Recommendation,
the Taipei Declaration, the Oviedo Convention, the
UNESCO Declaration on Genetic Data and the Council of
Europe Recommendation all discuss the right of an indivi-
dual to access their data, but there subtle differences. Under
the GDPR, the data subject has the right to access infor-
mation about their personal data including conﬁrmation as
to whether a data controller is processing their personal data
and the purpose, other recipients of their personal data
including to third countries (and the safeguards in place),
where the data controller obtained the data when the data
were not collected from the data subject, and expected
storage period or the criteria to determine the storage period
(Article 15). Article 15(3) also gives the data subject the
right to access a copy of their personal data that is being
processed. The Oviedo Convention states that individuals
are ‘entitled to know any information collected about his or
her health’ (Article 10(2)).
The WMA Taipei Declaration provides that individuals
have the right to request and be provided with information
about their data and requires health databases to adopt
measures so that they can inform individuals about their
activities (Article 14).
The 2017 OECD Guideline states that individuals must
be provided with ‘information about the processing of their
personal health data, including possible lawful access by
third parties, the underlying objectives behind the proces-
sing, the beneﬁts of the processing’. The Council of Europe
also speciﬁes that the management and use of the data
should be made available to ‘persons’ concerned’, but this
refers to the data collection in general and not the individual
data (Article 6(7)). The 2006 UNESCO Declaration states
that no one should be denied access to their data ‘unless
domestic law limits such access in the interest of public
health, public order or national security’ (Article 13).
There are limitations on this right to access. The GDPR
states that the right to access does not apply when the data
are anonymous and the right to access does fall within one
of the possible national derogations under Article 89(2).
The Oviedo Convention simply states that the right to
access may be restricted in ‘exceptional’ cases with no
further elaboration. The UNESCO Declaration on Genetic
Data also states that the right to access does not apply when
the data are anonymous and that the right to access can be
limited by law in ‘the interest of public health, public order
or national security’ (Article 13).
Some instruments also touch on feedback to participants
as distinct from access to data. Generally, where it is dis-
cussed, a policy on feedback is required, but not necessarily
that feedback must take place. Discussion on feedback of
ﬁndings is conﬁned to the non-binding instruments. The
2009 OCED Guidelines discusses ‘feedback’ to partici-
pants. It does not mandate that there is feedback to parti-
cipants, only that there is a policy in place (Principle 4.9)
and the results that can be feedback (Principle 4.14). The
annotations to the Guideline do state that participants
should be provided with information about the type of
research that may be carried out on the data, whether it will
be used for commercial research and if it will be transferred
abroad. The 2016 CoE Recommendation similarly states
that there must be a policy in place on feedback of ﬁndings
and the importance of counselling (Article 17).
Right to rectiﬁcation and right to erasure
The GDPR is alone in discussing the right to rectiﬁcation
and the right to erasure. None of the other instruments
reviewed discussed these rights. The right to erasure may be
linked to a right to withdraw from research as the with-
drawal from any study may include the erasure of a parti-
cipants’ data, but any recognised right to erasure would go
further than a right to withdrawal. The right to withdrawal is
arguably limited to ongoing and future research, whereas a
right to erasure would include the removal from future,
ongoing and past research, including potentially published
research.
The right to data portability and the right to object
Article 20 of the GDPR gives data subjects the right to
move their data from one data controller to another. The
2017 OECD Recommendation is the only other regulation
reviewed that provides that data subjects should be per-
mitted to request the sharing of their data for health-related
purposes, and if this is rejected, they must be provided with
a legal basis for that decision (Section 5(ii)(a) and (b)).
Article 21 of the GDPR provides data subjects with the
right to object to the processing of their personal data,
including for research purposes. Once again, the 2017
OECD Recommendation is the only regulation reviewed
that states that where consent is not the lawful basis of
processing, individuals should be able to object to the
processing of their personal information. If this cannot be
honoured, they should be provided with a relevant legal
basis for the decision (Section 5(ii) (a) and (b)).
Safeguards to protect data subjects
Article 89(1) of the GDPR states that safeguards ‘shall
ensure that technical and organisational measures are in
place in particular in order to ensure respect for the principle
of data minimisation’. These measures ‘may include pseu-
donymisation’, but offer no further insight into what they
may also be.
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Looking at the instruments reviewed, the importance of
clear governance procedures (and by implication, transpar-
ency) is essential in the oversight of the use and re-use of
data. This is of particular importance when the data subject
has not provided speciﬁc consent to the use of the data. This
may be in a manner prescribed by law, a requirement of
institutional oversight that may include approval by an
ethics committee or some other body, requirement of safe-
guards, or a combination. As outlined in Table 4, there are
three levels of oversight or protections discussed in the
instruments: a legislative framework, institutional oversight
that includes independent ethical review and provides for
other safeguards.
Discussion
The instruments reviewed have a different aim than the
GDPR [8], are speciﬁcally developed for research and they
do provide additional guidance that should be followed to
ensure that biobanks meet standard ethical practice. First,
although the derogations under the GDPR are potentially
quite wide ranging, the instruments reviewed put some
limits on these derogations, speciﬁcally in relation to the
right to information and the right to access. Regarding the
right to information, data subjects should be informed about
re-contact, feedback, storage, and withdrawal of consent
and any possible limits. Similarly, the instruments reviewed
do strongly suggest that data subjects should be able to
access their personal data, but a distinction is drawn
between access of data and feedback of ﬁndings/results. The
instruments do not mandate feedback of ﬁndings, but rather
state that a policy should be in place. Whether there is in
practice any real distinction between access of genetic data
and feedback of ﬁndings, it is clear that at a minimum,
biobanks should have a policy on feedback of ﬁndings in
place stating whether or not this is foreseen.
Second, the instruments do provide guidance on possible
safeguards. Article 89(1) and Article 89(2) speaks of the
importance of the rights and freedoms of the data subject’
and this should be considered when invoking the research
exemption. However, there is little guidance within the
GDPR itself on striking the balance between research and
individual rights. The words ‘in particular’ and ‘may
include’ in Article 89(1) of the GDPR indicates that the
safeguards include but are not conﬁned to technical and
organisational measures and pseudonymisation. The Article
29 WP (now the European Data Protection Board) states
that safeguards could include ‘Information Security Man-
agement Systems (e.g., ISO/IEC standards) based on the
analysis of information resources and underlying threats,
measures for cryptographic protection during storage and
transfer of sensitive data, requirements for authentication
and authorisation, physical and logical access to data, access
logging and others’ [9]. However, data protection is much
more than a technical issue requiring technical solutions and
the Article 29 WP has also spoken of the need for ‘addi-
tional legal, organisational and technical safeguards’ [9].
The safeguards must respond to the multitude of legal,
ethical and social risks that are associated with the sharing
of data. These risks are not static and change over time.
Thus, any safeguards must be dynamic and responsive to an
evolving science. In determining the safeguards that should
be adopted, this review makes it clear that any derogations
are subject to two pertinent factors.
First the importance of clear and transparent policies on a
multitude of issues is evident. These policies may include
policies on data transfer, feedback of ﬁndings, storage of
data, withdrawal of consent, re-contact of data subjects,
access requests from third parties, access requests of data
subjects, governance, and (where applicable) intellectual
property and commercial use. It is essential that biobanks
have these policies in place and that they are publicly
available. Having these policies available at the outset is
also in line with the GDPR’s policy of privacy by design
and default.
Second, it is evident that clear and transparent govern-
ance procedures that oversee the use of data are essential in
protecting the rights of the data subject. Once again this is in
line with the GDPR and the importance of transparency. A
coherent and robust governance structure is key in fostering
trust and trustworthiness that is so important in biobanking
[10]. What emerges from the instruments reviewed is that
there are broadly three levels to a governance structure that
Member States should follow: a national legal and ethical
framework; independent and interdisciplinary review and
oversight of the research; and local policies on data sharing
and protection.
At a minimum, national legislation should provide for
the legal basis of processing of personal data for research
Table 4 Governance required
for secondary use
Legislative framework Institutional oversight Subject to safeguards
Council of Europe 2016
recommendation; Universal Declaration
on the Human Genome and Human
Rights; OECD 2007 Principles;
UNESCO Declaration on Genetic Data
Council of Europe 2016
recommendation; Oviedo Convention;
CIOMS Guidelines; Declaration of
Helsinki; Taipei Declaration; UNESCO
Declaration on Genetic Data
GDPR; OECD 2017
recommendation
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purposes. The legislation should also mandate for local,
independent approval and oversight prior to the use of data
in research. Generally this will be in the form of institu-
tional research ethics review. However, while each research
project that seeks to collect and use personal data are
currently subject to independent ethics review, the sub-
sequent use and access of this data may not, with no body
ensuring that the rights of data subjects are protected.
Controlling access to the subsequent use of data are
essential to ensure that there are no undue risks to the
participant, and this review points to the importance of
independent review of access requests for data. An inde-
pendent body is best placed and likely to have the neces-
sary expertise to consider the potential heterogeneous risks
of an access request and these risks should not outweigh
the beneﬁts [11].
Third, each biobank must have transparent policies in
place regarding the use of personal data. They should
include but are not limited to policies on access, informa-
tion, use and re-use of data, transfer to third parties and
feedback of ﬁndings. These policies must be made pub-
lically available and submitted to a local ethics committee
as part of the research protocol.
Finally, members of an ethics committee may be faced
with a situation whereby a study under review meets the
requirements and derogations under the GDPR, but have
ethical concerns about the research. A resolution to this gap
between the law and ethics may in part depended on the
national legal order that is in place, but the purpose of such
committees is to ensure the ethical conduct of research. The
law is a minimal standard to which researchers must comply
with and the Article 29 Working Party Guidelines on con-
sent state that (where consent is the legal basis for proces-
sing) ‘consent for the use of personal data should be
distinguished from other consent requirements that serve as
an ethical standard or procedural obligation’ [12]. Ethics
committees are not necessarily under the obligation to
approve research that meets this legal threshold, but fails to
meet ethical criteria.
Conclusion
The GDPR provides for derogations on certain individual
rights for research on two separate grounds, but they must
be subject to safeguards and provided for by Member State
law. There is little insight or guidance contained within the
GDPR as to the appropriate safeguards that must be in
place, which is alarming considering the potential scope of
the derogations. This review makes it clear that a full
implementation of the derogations as provided for under the
GDPR may render the research unethical and not in line
with individuals interests. These instruments also suggest
that clear governance procedures and policies on the use
and re-use of personal data can go some way towards
ensuring that there are necessary safeguards in place to
ensure the protection of personal data. This would also
ensure that any derogations continue to be in line with the
GDPR’s transparency requirements and privacy by design
and default. By following these necessary safeguards,
biobanks can ensure that they may continue to conduct
research, which ensuring the protection of personal data.
In this way, research will not trump data protection,
but there will be a balance of the (at times) two competing
interests [13].
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